These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22938141)

  • 1. Current and emerging systemic treatment strategies for psoriasis.
    Laws PM; Young HS
    Drugs; 2012 Oct; 72(14):1867-80. PubMed ID: 22938141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in systemic immunomodulatory therapy for psoriasis.
    Berger EM; Gottlieb AB
    Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A; Molinelli E; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
    Caiazzo G; Fabbrocini G; Di Caprio R; Raimondo A; Scala E; Balato N; Balato A
    Front Immunol; 2018; 9():1668. PubMed ID: 30150978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target.
    Botti E; Spallone G; Caruso R; Monteleone G; Chimenti S; Costanzo A
    Curr Pharm Biotechnol; 2012 Aug; 13(10):1861-7. PubMed ID: 22250707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Biologics in the Treatment of Moderate-to-Severe Plantar Psoriasis.
    Ekladios J; Jolliffe J; Panchigar S; Qureshi R; Shete A; Wellner J; Vlahovic TC
    Clin Podiatr Med Surg; 2021 Oct; 38(4):553-559. PubMed ID: 34538433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
    Gan EY; Chong WS; Tey HL
    BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W
    Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's New in Psoriasis.
    von Csiky-Sessoms S; Lebwohl M
    Dermatol Clin; 2019 Apr; 37(2):129-136. PubMed ID: 30850034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics for psoriasis: What is new?
    Özyurt K; Ertaş R; Atasoy M
    Dermatol Ther; 2019 May; 32(3):e12916. PubMed ID: 30972872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
    Gaspari AA; Tyring S
    Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles of biological therapy in psoriasis.
    Caca Biljanovska N; V'lckova Laskoska M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(1):143-53. PubMed ID: 23928807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term data in the treatment of psoriasis.
    Thaçi D
    Br J Dermatol; 2008 Aug; 159 Suppl 2():18-24. PubMed ID: 18700911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.